Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Feb 22, 2011)
  • 8-K (Feb 15, 2011)
  • 8-K (Feb 1, 2011)
  • 8-K (Jan 20, 2011)
  • 8-K (Jan 18, 2011)
  • 8-K (Jan 12, 2011)

 
Other

Matrixx Initiatives 8-K 2007

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.2
  4. Ex-99.3
  5. Ex-99.4
  6. Ex-99.5
  7. Ex-99.5
e8vk
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 22, 2007
MATRIXX INITIATIVES, INC.
(Exact Name of Registrant as Specified in its Charter)
         
Delaware   001-31404   87-0482806
         
(State of Incorporation)   (Commission File Number)   (IRS Employer
Identification Number)
4742 N. 24th Street, Suite 455, Phoenix, Arizona 85016
(Address of principal executive offices)
(602) 385-8888
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 8.01 Other Events
SIGNATURES
Exhibit 99.1
Exhibit 99.2
Exhibit 99.3
Exhibit 99.4
Exhibit 99.5


Table of Contents

Item 5.02.   Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On January 22, 2007, Michael Voevodsky resigned from his position as Vice President of Marketing of Matrixx Initiatives, Inc. (the “Company”), effective January 31, 2007 (the “Effective Date”).
     In connection with his resignation, the Company and Mr. Voevodsky entered into a severance agreement (the “Severance Agreement”), that provides for a six-month severance payment in the amount of $95,500, less all lawfully required withholdings; the Company’s payment for a period of six months of Mr. Voevodsky’s health insurance and outplacement expenses; and allows for exercise of his outstanding stock options for 90 calendar days after the Effective Date. In addition, if, between February 1, 2007 and August 1, 2007, the Company experiences a change in control, Mr. Voevodsky will receive an additional severance payment of $95,500 and a payment equal to the average of his incentive bonuses for fiscal 2005 and 2006.
Item 8.01   Other Events.
     Product Liability Litigation Update
     Company Statement. As previously reported, numerous lawsuits have been filed against the Company alleging that our Zicam Cold Remedy nasal gel product has caused the permanent loss or diminishment of the sense of smell or smell and taste. See “Legal Proceedings — Product Liability Matters” in Note 7 of Notes to Condensed Consolidated Financial Statements in the Company’s Report on Form 10-Q for the fiscal quarter ended September 30, 2007. We believe these allegations are scientifically unfounded and misleading and we continue to vigorously defend the lawsuits that have been filed against us. On January 25, 2007, we issued a statement (the “Company Statement”) regarding the ongoing confusion about the use of intranasal zinc gluconate and anecdotal reports of loss of smell. A copy of the Company Statement is attached to this Report on Form 8-K as Exhibit 99.1.
     Recent Court Rulings. Federal law and the law of many states requires that the testimony of a scientific or medical expert witness be reliable and based on valid scientific data and analysis before it can be allowed into evidence. To date, the Company has submitted motions in eight federal lawsuits against the Company challenging the reliability and admissibility of the testimony of expert witnesses who claim that Zicam is capable of causing or has caused smell and taste loss. To date, the courts have ruled on four of the eight motions. Each court has ruled that the testimony of the experts lacks reliability and a sufficient scientific basis for admission into evidence. The four cases in which orders have been granted are: Hans, et al. vs. Matrixx Initiatives, Inc., et al., filed September 13, 2004, in the United States District Court for the Western District of Kentucky; Sutherland v. Matrixx Initiatives, Inc., et al., filed December 18, 2003, in the United States District Court for the Northern District of Alabama, Middle Division;

2


Table of Contents

Benkwith et al. v. Matrixx Initiatives, Inc., et al., filed May 3, 2004, in the United States District Court for the Northern District of Alabama, Middle Division; and O’Hanlon, et al. v. Matrixx Initiatives, Inc., et al., filed October 29, 2004, in the United States District Court for the Central District of California.
     In Sutherland, Benkwith, and O’Hanlon, the courts dismissed the case simultaneously with their ruling to exclude the expert testimony; in Hans, a motion for dismissal is pending. Exclusive of Hans, there remain 16 federal lawsuits pending against the Company. Of the 16, three have been settled for immaterial amounts and are expected to be dismissed in the near future and four are awaiting rulings on the motions referenced above challenging the reliability and admissibility of expert witness testimony.
     Copies of the four court orders are attached to this Report on Form 8-K as Exhibits 99.2, 99.3, 99.4, and 99.5.

3


Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                 
Date: January 26, 2007
               
 
               
        MATRIXX INITIATIVES, INC.    
 
               
 
      By:   /s/ William J. Hemelt    
 
               
 
          William J. Hemelt
Executive Vice President, Chief
Financial Officer and Treasurer
   

4

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki